MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-19-0001255
Market Cap
₹134 Cr
AUROLAB · BSE
Share Price
₹219.00
+2.10% today
Revenue
₹30.74 Cr
FY 2025-26 · +60.8% YoY
EBITDA
₹9.86 Cr
Margin 32.1%
Net Profit
₹3.79 Cr
FY 2025-26 · +108.2% YoY
P/E (TTM)
77.5x
P/B 3.3x
ROE
7.9%
ROCE 9.2%
Debt / Equity
1.21
Interest cover 60.3x
About Auro Laboratories Limited
Data last updated:
Auro Laboratories Limited is a public limited company based in Thane, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 26 May 1989 and has been in existence for over 37 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L33125MH1989PLC051910. Its GSTIN is 27AAACA3977D1ZS (Maharashtra). It is a listed company as per MCA records. Its shares are listed on BSE: 530233.
The company has an authorised share capital of ₹7 Cr and a paid-up capital of ₹6.23 Cr. It is led by directors including Sharat Deorah (Managing Director) and Siddhartha Deorah (Whole-Time Director).
Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at K – 56 M I D Ctarapur Industrial Area, Thane, Maharashtra, India – 401506.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹30.74 Cr, a growth of 60.8% compared to the previous year. For the same year it recorded a net profit of ₹3.79 Cr (net margin 12.3%) and EBITDA of ₹9.86 Cr (EBITDA margin 32.1%). The net worth stands at ₹46.35 Cr (up 7.9% YoY). Total assets are valued at ₹109.85 Cr (up 24.9% YoY).
The company is associated with 2 brands: Auro Laboratories and Aurolab. As per MCA filings, the company has open charges of ₹81.19 Cr and satisfied charges of ₹11.97 Cr on record. Court records list 46 cases involving the company, including 21 filed by the company and 25 filed against it; 2 cases are pending. The company has 7 deals on record (7 market trades); the latest was in August 2023. Its 7 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 2 smaller; the largest is Tosco Pharma Private Limited with revenue of ₹20.42 Cr.
Auro Laboratories Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0001255). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aurolabs.com.
Company details
CIN L33125MH1989PLC051910
Registration Number 051910
Incorporation Date 26 May 1989
ROC Mumbai
Listing Status Listed - Listed on BSE (530233)
Company Status Active
Date of Last AGM 25 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-MH-19-0001255
CIN history
Auro Laboratories has one previous CIN (Corporate Identification Number): U33125MH1989PLC051910. The current CIN is L33125MH1989PLC051910, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L33125MH1989PLC051910 | Current |
| U33125MH1989PLC051910 | Previous |
Key People
Sharat Deorah Managing Director Siddhartha Deorah Whole-Time Director Kiran Suresh Kulkarni Whole-Time Director Recognitions & Rankings of Auro Laboratories
Contact details
Auro Laboratories Limited's registered office is in Thane, Maharashtra. Its website is aurolabs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressK – 56 M I D Ctarapur Industrial Area, Thane, Maharashtra, India – 401506
- IndustryPharma, API Manufacturers
To see the full contact details of Auro Laboratories Limited, buy the company report.
Comprehensive company report
Auro Laboratories Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Auro Laboratories operates two associated brands: Auro Laboratories and Aurolab. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Active pharmaceutical ingredients and intermediates are manufactured for pharmaceutical applications. | aurolabs.com | |
| Manufacturer of high quality ophthalmic consumables | aurolab.com |
Business activity
The main business activity of Auro Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Auro Laboratories Limited, buy the company report.
Financials of Auro Laboratories Limited
FY 2025-26 filings availableAuro Laboratories Limited reported revenue of ₹30.74 Cr (up 60.8% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹30.74 Cr
+60.8% YoY
EBITDA
₹9.86 Cr
+217.0% YoY
Profit After Tax
₹3.79 Cr
+108.2% YoY
Net Worth
₹46.35 Cr
+7.9% YoY
Total Assets
₹110 Cr
+24.9% YoY
Total Debt
₹63.31 Cr
+40.7% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 30.74 | 19.12 | 53.64 | 52.89 | 50.87 | 54.25 | 43.79 |
| Revenue growth | +60.8% | -64.4% | +1.4% | +4.0% | -6.2% | +23.9% | - |
| EBITDA | 9.86 | 3.11 | 10.67 | 4.39 | 4.62 | 11.23 | 6.27 |
| EBITDA margin | +32.1% | +16.3% | +19.9% | +8.3% | +9.1% | +20.7% | +14.3% |
| Profit before tax | 4.81 | 1.86 | 10.34 | 3.45 | 3.86 | 10.49 | 5.64 |
| Net profit | 3.79 | 1.82 | 7.79 | 2.45 | 2.83 | 7.17 | 4.06 |
| Net profit margin | +12.3% | +9.5% | +14.5% | +4.6% | +5.6% | +13.2% | +9.3% |
| EPS (₹) | 5.67 | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 | 6.51 |
| Balance sheet | |||||||
| Total assets | 110 | 87.98 | 68.20 | 40.61 | 45.30 | 31.74 | 24.65 |
| Net worth | 46.35 | 42.97 | 41.96 | 34.20 | 31.52 | 28.58 | 21.50 |
| Total debt | 63.31 | 45.01 | 26.25 | 6.41 | 13.78 | 3.16 | 3.16 |
| Cash & bank | 1.67 | 0.63 | 1.65 | 2.42 | 12.40 | 14.54 | 5.68 |
| Net working capital | 22.20 | 11.16 | 14.78 | 21.93 | 29.61 | 19.69 | 11.81 |
| Cash flow | |||||||
| Cash from operations | 2.11 | 5.02 | 18.81 | 3.28 | (6.59) | 12.82 | 9.30 |
| Cash from investing | (14.78) | (23.70) | (38.67) | (5.08) | (5.34) | (3.51) | (2.21) |
| Cash from financing | 14.04 | 17.69 | 19.09 | (8.18) | 9.79 | (0.46) | (5.52) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.77 | 9.83 | 9.39 | 8.84 | 2.77 | 7.40 | 3.05 | 3.10 |
| Revenue growth (YoY) | +216.6% | +32.8% | +207.9% | +185.2% | -51.6% | - | - | - |
| Other income | 0.11 | 0.66 | 0.18 | 0.98 | 0.42 | 0.13 | 0.14 | 0.31 |
| Total expenses | 5.46 | 6.65 | 5.33 | 6.48 | 2.74 | 6.59 | 2.61 | 2.38 |
| EBITDA | 3.31 | 3.18 | 4.06 | 2.36 | 0.03 | 0.81 | 0.44 | 0.72 |
| EBITDA margin | +37.7% | +32.3% | +43.2% | +26.7% | +1.1% | +10.9% | +14.4% | +23.2% |
| Depreciation | 0.91 | 0.90 | 0.98 | 0.65 | 0.27 | 0.29 | 0.27 | 0.27 |
| Interest | 1.37 | 1.49 | 1.52 | 0.96 | 0.28 | 0.30 | 0.25 | 0.28 |
| Profit before tax | 1.14 | 1.45 | 1.74 | 1.73 | (0.10) | 0.35 | 0.06 | 0.48 |
| Tax | 0.08 | 0.48 | (0.21) | 1.00 | 0.00 | (0.04) | 0.02 | 0.12 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.77 | 9.83 | 9.39 | 8.84 | 2.77 | 7.40 | 3.05 | 3.10 |
| Revenue growth (YoY) | +216.6% | +32.8% | +207.9% | +185.2% | -51.6% | - | - | - |
| Other income | 0.11 | 0.66 | 0.18 | 0.98 | 0.42 | 0.13 | 0.14 | 0.31 |
| Total expenses | 5.46 | 6.65 | 5.33 | 6.48 | 2.74 | 6.59 | 2.61 | 2.38 |
| EBITDA | 3.31 | 3.18 | 4.06 | 2.36 | 0.03 | 0.81 | 0.44 | 0.72 |
| EBITDA margin | +37.7% | +32.3% | +43.2% | +26.7% | +1.1% | +10.9% | +14.4% | +23.2% |
| Depreciation | 0.91 | 0.90 | 0.98 | 0.65 | 0.27 | 0.29 | 0.27 | 0.27 |
| Interest | 1.37 | 1.49 | 1.52 | 0.96 | 0.28 | 0.30 | 0.25 | 0.28 |
| Profit before tax | 1.14 | 1.45 | 1.74 | 1.73 | (0.10) | 0.35 | 0.06 | 0.48 |
| Tax | 0.08 | 0.48 | (0.21) | 1.00 | 0.00 | (0.04) | 0.02 | 0.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 30.74 | 19.12 | 53.64 | 52.89 | 50.87 | 54.25 | 43.79 |
| Revenue growth | +60.8% | -64.4% | +1.4% | +4.0% | -6.2% | +23.9% | - |
| Other income | 2.01 | 0.93 | 1.50 | 0.94 | 1.09 | 0.76 | 0.97 |
| Total expenses | 20.88 | 16.01 | 42.97 | 48.50 | 46.25 | 43.02 | 37.52 |
| Employee cost | 5.86 | 2.47 | 3.91 | 3.76 | 3.70 | 3.64 | 3.48 |
| EBITDA | 9.86 | 3.11 | 10.67 | 4.39 | 4.62 | 11.23 | 6.27 |
| EBITDA margin | +32.1% | +16.3% | +19.9% | +8.3% | +9.1% | +20.7% | +14.3% |
| Depreciation | 2.81 | 1.10 | 1.09 | 1.07 | 1.02 | 1.04 | 1.02 |
| Interest | 4.25 | 1.08 | 0.74 | 0.81 | 0.83 | 0.46 | 0.58 |
| Profit before tax | 4.81 | 1.86 | 10.34 | 3.45 | 3.86 | 10.49 | 5.64 |
| Tax | 1.28 | 0.04 | 2.55 | 1.00 | 1.03 | 3.32 | 1.58 |
| Net profit | 3.79 | 1.82 | 7.79 | 2.45 | 2.83 | 7.17 | 4.06 |
| Net profit margin | +12.3% | +9.5% | +14.5% | +4.6% | +5.6% | +13.2% | +9.3% |
| EPS (₹) | 5.67 | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 | 6.51 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 |
| Reserves & surplus | 40.12 | 36.74 | 35.73 | 27.97 | 25.29 | 22.35 | 15.27 |
| Shareholders' funds (net worth) | 46.35 | 42.97 | 41.96 | 34.20 | 31.52 | 28.58 | 21.50 |
| Secured loans | 58.61 | 42.71 | 26.18 | 6.01 | 8.13 | 1.93 | 1.81 |
| Unsecured loans | 4.70 | 2.30 | 0.07 | 0.40 | 5.65 | 1.23 | 1.35 |
| Total debt | 63.31 | 45.01 | 26.25 | 6.41 | 13.78 | 3.16 | 3.16 |
| Total liabilities | 110 | 87.98 | 68.20 | 40.61 | 45.30 | 31.74 | 24.65 |
| Assets | |||||||
| Gross block | 89.14 | 36.10 | 36.10 | 25.47 | 25.35 | 24.28 | 23.96 |
| Net block | 75.18 | 21.06 | 22.15 | 12.62 | 13.60 | 13.55 | 14.23 |
| Capital work in progress | 14.48 | 56.48 | 32.68 | 7.67 | 3.68 | 0.13 | 0.12 |
| Investments | 0.01 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Inventories | 13.54 | 3.67 | 8.24 | 11.76 | 4.25 | 2.55 | 4.06 |
| Sundry debtors | 9.15 | 9.39 | 13.39 | 12.40 | 13.61 | 7.30 | 5.78 |
| Cash & bank balances | 1.67 | 0.63 | 1.65 | 2.42 | 12.40 | 14.54 | 5.68 |
| Loans & advances | 6.40 | 7.18 | 7.57 | 9.08 | 7.36 | 3.77 | 2.42 |
| Total current assets | 30.76 | 20.87 | 30.85 | 35.66 | 37.62 | 28.16 | 17.94 |
| Total current liabilities | 8.56 | 9.71 | 16.07 | 13.73 | 8.01 | 8.47 | 6.13 |
| Net working capital | 22.20 | 11.16 | 14.78 | 21.93 | 29.61 | 19.69 | 11.81 |
| Total assets | 110 | 87.98 | 68.20 | 40.61 | 45.30 | 31.74 | 24.65 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.00 | 0.99 | 2.42 | 12.40 | 14.54 | 5.68 | 4.11 |
| Net cash from operating activities | 2.11 | 5.02 | 18.81 | 3.28 | (6.59) | 12.82 | 9.30 |
| Net cash from investing activities | (14.78) | (23.70) | (38.67) | (5.08) | (5.34) | (3.51) | (2.21) |
| Net cash from financing activities | 14.04 | 17.69 | 19.09 | (8.18) | 9.79 | (0.46) | (5.52) |
| Net change in cash | 1.37 | (0.99) | (0.77) | (9.98) | (2.14) | 8.85 | 1.58 |
| Closing cash | 1.67 | 0.63 | 1.65 | 2.42 | 12.40 | 14.54 | 5.68 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +60.8% | -64.4% | +1.4% | +4.0% | -6.2% | +23.9% | - |
| EBITDA growth | +217.0% | -70.9% | +143.1% | -5.0% | -58.9% | +79.1% | - |
| PBT growth | +158.6% | -82.0% | +199.7% | -10.6% | -63.2% | +86.0% | -7.1% |
| Net income growth | +108.2% | -76.6% | +218.0% | -13.4% | -60.5% | +76.6% | - |
| Revenue CAGR (3Y) | -16.6% | -27.8% | -0.4% | +6.5% | +2.8% | +10.0% | +7.3% |
| EBITDA CAGR (3Y) | +31.0% | -12.4% | -1.7% | -11.2% | -12.9% | +20.9% | +12.3% |
| Profitability & leverage | |||||||
| Net income margin | +11.5% | +9.5% | +14.5% | +4.6% | +5.6% | +13.2% | +9.3% |
| Return on capital employed | +9.2% | +3.8% | +20.4% | +9.9% | +12.2% | +38.9% | +24.8% |
| Return on net worth | +7.9% | +4.3% | +20.5% | +7.4% | +9.5% | +28.7% | +20.8% |
| Debt / equity | 1.21 | 0.84 | 0.43 | 0.31 | 0.28 | 0.13 | 0.29 |
| Long-term debt / equity | 0.86 | 0.61 | 0.27 | 0.06 | 0.07 | 0.11 | 0.29 |
| Interest cover | 60.28 | 53.73 | 7.72 | 24.40 | 23.06 | 4.51 | 11.05 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.49 | 0.53 | 1.74 | 2.08 | 2.05 | 2.25 | 1.85 |
| Inventory turnover | 3.57 | 3.21 | 5.36 | 6.61 | 14.96 | 16.41 | 11.79 |
| Debtors turnover | 3.32 | 1.68 | 4.16 | 4.07 | 4.87 | 8.30 | 6.13 |
| EPS (₹) | 5.67 | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 | 6.51 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 74.36 | 68.94 | 67.32 | 54.87 | 50.58 | 45.86 | 34.49 |
To see the full year-wise statements and ratios of Auro Laboratories Limited, buy the company report.
Board of directors of Auro Laboratories Limited
Auro Laboratories has 6 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kavita Vijayakant Sharma | Director | 27 Mar 2015 | 11 Years 6 Months | Current |
| Siddhartha Deorah Also directs: Auro Impex Pvt Ltd | Whole-Time Director | 16 Dec 2013 | 12 Years 10 Months | Current |
| Kiran Suresh Kulkarni | Whole-Time Director | 24 May 2021 | 5 Years 4 Months | Current |
| Sharat Deorah Also directs: Auro Impex Pvt Ltd | Managing Director | 26 May 1989 | 37 Years 4 Months | Current |
| Mahendra Kumar Daga | Director | 01 Apr 2024 | 2 Years 6 Months | Current |
| Vishal Kailashchandra Jhunjhunwala | Director | 23 Aug 2023 | 3 Years 2 Months | Current |
Peer comparison
Auro Laboratories Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Auro Laboratories Limitedthis company | ₹30.74 Cr (FY 2026) | ₹3.79 Cr | 12.3% | 60.8% | Thane, Maharashtra, India | |
| Tosco Pharma Private Limited | ₹20.42 Cr (FY 2024) | 337.0% | Hyderabad, Telangana, India | |||
| Tesla Chemicals Private Limited | ₹20.24 Cr (FY 2025) | -18.0% | Panoli, Gujarat, India | |||
| Pharchem Private Limited | ₹20.2 Cr (FY 2024) | 0.0% | Boisar, Maharashtra, India | |||
| Suyog Life Sciences Private Limited | ₹20.09 Cr (FY 2025) | -1.0% | Ankleshwar, Gujarat, India | |||
| Frinze Laboratories Private Limited | ₹20.07 Cr (FY 2025) | 12.0% | Hyderabad, Telangana, India | |||
| Asai Vishwa Speciality Chemicals Private Limited | ₹19.73 Cr (FY 2024) | -13.0% | Navi Mumbai, Maharashtra, India | |||
| Taaj Health Care Chemicals Private Limited | ₹19.54 Cr (FY 2024) | 233.0% | Thane, Maharashtra, India |
To see the full peer comparison of Auro Laboratories Limited, buy the company report.
Auditor
Auro Laboratories Limited is audited by Kothari Jain & Associates for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Kothari Jain & Associates | FY 2024 | 113041W |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 52.20%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 47.80%.
Mar 2026
QUARTER
52.20% Promoters
47.80% Retail & Others
Promoter holding - history
Now 52.20% · Mar 2026High 52.20% · Jun 2025Low 52.20% · Jun 2025
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 52.20% | 52.20% | 52.20% | 52.20% |
| Public | 47.80% | 47.80% | 47.80% | 47.80% |
Charges & borrowings
Open charges
₹81.19 Cr
Satisfied charges
₹11.97 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 25 Feb 2026 | 101256081 | Indian Bank | ₹18.9 Lakh | Open | |
| 30 Dec 2025 | 101210615 | Hdfc Bank Limited | ₹13 Cr | Open | |
| 29 Feb 2024 | 100891365 | Indian Bank | ₹20 Lakh | Open | |
| 20 Dec 2002 | 90240936 | Indian Bank | ₹67.8 Cr | Open | |
| 21 Jul 2025 | 101138770 | Indian Bank | ₹1.8 Cr | Satisfied |
To see the full charge records of Auro Laboratories Limited, buy the company report.
Total charge records: 17 View all charges
Deals & funding
Auro Laboratories Limited has 7 deals on record (7 market trades); the latest was in August 2023.
Total deals
7
Market trades
7
Deals on record (5 of 7)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2023 | Market trade | ₹67.4 Lakh | Buyer: Padrone Marketing Pvt Ltd |
| Jun 2023 | Market trade | ₹25.2 Lakh | Seller: an individual |
| May 2023 | Market trade | ₹97.6 Lakh | Buyer: an individual |
| Jan 2022 | Market trade | ₹59.1 Lakh | Seller: an individual |
| Apr 2021 | Market trade | ₹54.4 Lakh | Seller: an individual |
To see the full deal history of Auro Laboratories Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Auro Laboratories Limited has 46 court cases on record: 21 filed by Auro Laboratories, 25 filed against it. 2 cases are pending and 44 are disposed.
Total cases
46
Filed by the company
21
Filed against the company
25
Pending
2
Disposed
44
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 31 | 18 | 0 |
| District courts | 13 | 7 | 1 |
| Supreme Court | 1 | 0 | 1 |
| NCLT | 1 | 0 | 0 |
Cases on record (5 of 46)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Supreme Court | Court case (1503-Appeal Against Orders Of Statutory Bodies : Tribunals) | Filed by the company against Tarapur Environment Protection Society Represented by Its Chairman Plot No. Am-29/Pt, NR Shivaji Nagar, Midc Tarapur Dist Thane , , Maharashtra and 11 others | Pending |
| Calcutta High Court | Court case (CRR) | Filed by the company against National Plywood Industries Limited | Disposed |
| High Court | Court case (EC) | Filed by the company against Maikaal Fibres Limited | Disposed |
| High Court | Civil suit | Filed by the company against Maikaal Fibres Ltd. | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Court case (S S) | Filed by the company against Hitechi Jewellery Industries Ltd., 6 Othrs | Disposed |
To see the full case history of Auro Laboratories Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Auro Laboratories Limited was last rated by Crisil on 27 Aug 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 27 Aug 2020 |
To see the full credit ratings and regulatory alerts of Auro Laboratories Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Auro Laboratories Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Auro Laboratories has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACA3977D1ZS | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Auro Laboratories Limited, buy the company report.
Recent activity
Auro Laboratories Limited has 14 board changes on record since 1989: 10 appointments and 4 cessations. The latest: Mahendra Kumar Daga was appointed as Director on 01 Apr 2024.
Filing
Auro Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai Ii.
Charges
A charge with Indian Bank amounted to Rs. 0.19 Cr with Charge ID 101256081 was registered on 25 Feb 2026.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 13.00 Cr with Charge ID 101210615 was registered on 30 Dec 2025.
Charges
A charge registered on 21 Jul 2025 via Charge ID 101138770 with Indian Bank was fully satisfied on 19 Nov 2025.
Charges
A charge with Indian Bank of Rs. 67.80 Cr registered on 20 Dec 2002 with Charge ID 90240936 was modified on 04 Nov 2025.
AGM
Auro Laboratories Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Charges
A charge registered on 21 Mar 2025 via Charge ID 101077650 with Indian Bank was fully satisfied on 11 Aug 2025.
Charges
A charge with Indian Bank amounted to Rs. 1.80 Cr with Charge ID 101138770 was registered on 21 Jul 2025.
Charges
A charge with Indian Bank amounted to Rs. 1.80 Cr with Charge ID 101077650 was registered on 21 Mar 2025.
Appointed
Mahendra Kumar Daga was appointed as Director.
Ceased
Kailash Chand Bubna ceased to be Director.
Charges
A charge with Indian Bank amounted to Rs. 0.20 Cr with Charge ID 100891365 was registered on 29 Feb 2024.
37 earlier events are in the company report.
News
Frequently asked questions
Auro Laboratories is an active public limited company based in Thane, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 26 May 1989 (37+ years old) and is registered under CIN L33125MH1989PLC051910. Listed on BSE: 530233.
Auro Laboratories reported revenue of ₹30.74 Cr for FY 2025-26 (up 60.8% YoY) based on standalone financials.
Auro Laboratories has 6 current directors:
- Sharat Deorah - Managing Director
- Siddhartha Deorah - Whole-Time Director
- Kiran Suresh Kulkarni - Whole-Time Director
- Kavita Vijayakant Sharma - Director
- Mahendra Kumar Daga - Director
- Vishal Kailashchandra Jhunjhunwala - Director
The latest financial statements of Auro Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Auro Laboratories is 27AAACA3977D1ZS, registered in Maharashtra.
The CIN (Corporate Identification Number) of Auro Laboratories is L33125MH1989PLC051910. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Auro Laboratories is a listed company as per MCA records. Its shares are listed on BSE (code: 530233).
Auro Laboratories has 46 court cases on record: 21 filed by the company and 25 filed against it. 2 are pending. Most are in the high courts.
Auro Laboratories was incorporated on 26 May 1989, making it 37+ years old. It is registered with the Registrar of Companies, Mumbai.
Auro Laboratories has 7 deals on record (7 market trades); the latest was in August 2023.
The peers of Auro Laboratories by revenue are Tosco Pharma Private Limited, Tesla Chemicals Private Limited, Pharchem Private Limited, Suyog Life Sciences Private Limited, Frinze Laboratories Private Limited and 2 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).